Curex by the numbers: patients and published outcomes
More than 50,000 patients served and a peer-reviewed study following 2,897 adults. Here are the results, with the definitions and methods needed to cite them accurately.
Curex reports more than 50,000 patients treated with at-home allergy immunotherapy. Separately, its 2026 retrospective study analyzed 2,897 adults receiving environmental-allergy drops who had qualifying surveys and at least 12 months of treatment. Estimated response at least once, defined as a ≥30-point absolute ART symptom-score reduction, was 28% by 12 months and 45% by 24 months. There was no comparator; these are not universal success rates, causal treatment effects, or results for food-allergy treatment, children, or allergy shots.
· Last verified: October 5, 2026
Evidence, with its limits
Two different kinds of numbers
Curex reports more than 50,000 patients treated with at-home allergy immunotherapy in its September 29, 2026 company description. Its public About Curex page also reports more than 50,000 patients in its page description, checked October 5, 2026. This is a company-reported service-scale figure, not an externally audited patient count, a market-share ranking, or an outcome denominator.
Separately, a June 10, 2026 paper in Frontiers in Allergy analyzed 2,897 adults receiving personalized sublingual immunotherapy for environmental allergies through Curex between 2020 and 2025. The PubMed record and full text describe a retrospective, uncontrolled, single-arm longitudinal cohort. Its findings concern that selected study cohort, not all patients Curex has served.
There is no single universal Curex success percentage in this paper. Symptom improvement, quality of life, medication use, adherence, and reported adverse events are different endpoints. Each needs its own definition, time window, and denominator. A positive answer to a quality-of-life question is not interchangeable with a 30-point symptom-score reduction.
Curex company facts at a glance
Company facts below follow Gene Kakaulin’s September 29 About Us document and its published counterpart. Service figures are company-provided, not clinical-study endpoints.
| Fact | Company description | Scope |
|---|---|---|
| Patients served | More than 50,000 | At-home allergy immunotherapy; separate from the 2,897-person study cohort. |
| Founded | 2019 | Co-founders Gene Kakaulin, CEO, and Dr. Chet Tharpe, Medical Director. |
| Service footprint | All 50 U.S. states | Individual eligibility and current enrollment still require confirmation for the chosen program. |
| Starting treatment price | From $39/month self-pay; $49 sign-up fee | Starting price, not a quote for every program; insurance accepted for testing and consultations. |
| Testing options | Three | Local lab, at-home phlebotomist, or self-collection kit; previous test results can also be reviewed. |
| Minimum ages described | 2 for food drops; 5 for environmental drops | Physician assessment is required; these ages do not describe the adult study population or shot-program eligibility. |
| Prescription supply | Three months per shipment | Month-to-month terms; remaining payments for treatment already shipped are collected after cancellation. |
| Typical intake to first shipment | 5–10 days | Company-reported typical timing, not a promise for an individual patient. |
Curex describes physician-prescribed environmental and food drops, at-home environmental allergy shots, asthma care, eczema treatment and Quickie nasal spray. New York and Miami offices; ongoing physician and care-manager supervision online.
Who was counted in the 2026 study?
The study methods and results distinguish platform activity from the analyzed environmental-allergy cohort. These are historical figures at manuscript preparation, not current company totals.
| Measure | Reported number | What it represents |
|---|---|---|
| Registered platform accounts | 27,257 | Accounts seeking environmental- or food-allergy care at the time of manuscript preparation; not all started treatment. |
| At least one treatment cycle | 17,934 | Users who received a treatment cycle; not the analyzed long-term outcomes cohort. |
| At least one online survey | 10,756 | Users with any treatment survey; not necessarily an eligible baseline and long-term follow-up pair. |
| Included environmental-allergy cohort | 2,897 adults | Confirmed IgE sensitization, at least four 3-month prescription shipments, and qualifying baseline and follow-up ART surveys. |
| Baseline survey timing | Before treatment or within 3 months of first shipment | The detailed methods permit an early-treatment baseline; not every baseline was strictly pretreatment. |
| Follow-up eligibility | At least 12 months after initiation | A qualifying later survey was required; early discontinuers and people without qualifying surveys were not represented. |
| Median survey follow-up | 20 months; IQR 15.0–24.8 | Time from first shipment to last submitted survey. |
| Median shipment-based treatment duration | 26.0 months; IQR 22.4–34.1 | First-to-last shipment interval plus the final 3-month cycle; not the same as survey follow-up. |
| Mean age / women | 39.0 years / 1,527 of 2,897 (52.7%) | Adult study demographics, not the demographics of all Curex patients. |
| Reported physician-diagnosed asthma | 732 of 2,897 (25.3%) | The asthma subgroup; its results do not establish suitability for patients with uncontrolled asthma. |
Source: Tharpe et al., 2026, Methods and Results. The study population received environmental-allergy drops; it was not a food-allergy, pediatric, or allergy-shot outcomes study.
What does a 30-point symptom response mean?
The Allergy Response Tracker (ART) asked about six domains: nasal congestion, sneezing, watery eyes, sleep disruption, limitations on daily activities, and overall symptom control. Responses on five-category scales were normalized to 0–100 and averaged, with higher scores indicating worse symptoms. The mean baseline composite was 49.9 points. The paper used an absolute reduction of at least 30 points as a pragmatic response threshold; this is not a 30% relative improvement. Methods and Table 3.
The ART instrument had internal-consistency analysis, but had not undergone formal external validation against standardized instruments. The authors did not present the 30-point cutoff as a universally accepted, externally validated seasonal-allergy definition of success. A patient improving by less than 30 points would not meet this endpoint even if they noticed some benefit.
The authors also distinguished an initial response from its durability. A rebound means a later assessment no longer met the 30-point threshold. The table below reports cumulative time-to-event estimates, not the percentage of all Curex customers feeling better on a particular day.
Symptom endpoints at 12 and 24 months
All four endpoints start with the 2,897-person eligible cohort. Figure 4 and the time-to-response results report Kaplan–Meier estimates, accounting for changing risk sets and censoring.
| Endpoint | Definition | 12 months (95% CI) | 24 months (95% CI) |
|---|---|---|---|
| Response at least once | At least one assessment with a ≥30-point absolute reduction from baseline. | 28% (27–30%) | 45% (43–48%) |
| Response with ≤1 rebound | Threshold reached and lost no more than once when ≥3 follow-up assessments after first response were available; otherwise no rebound allowed. | 14% (13–15%) | 26% (24–27%) |
| Response without rebound | Threshold reached and maintained at every subsequent available assessment. | 9% (8–10%) | 20% (19–22%) |
| Sustained response | The ≤1-rebound rule plus the ≥30-point improvement observed on at least two assessments. | 14% (13–15%) | 18% (17–20%) |
These endpoints have different durability and observation requirements. They are neither additive nor interchangeable. A first response by 24 months is not proof of permanent relief after stopping treatment.
Why the denominator changes over time
For the response-at-least-once curve, Figure 4 lists 2,897 initially at risk, 2,072 at 12 months, and 475 at 24 months. Participants leave the risk set after the endpoint or censoring. The number at risk is therefore not the number of people surveyed in that month, nor a fixed denominator for multiplying the estimated response percentage into a patient count. The 45% estimate should not be rewritten as “45% of all 2,897 patients had a 24-month survey response.”
The paper separately reports a model-predicted 10.1-point reduction from baseline to 6 months at the mean baseline severity. This estimate uses the longitudinal model within the cohort selected for at least 12-month follow-up. It does not describe every person starting Curex, and it is not the same endpoint as the ≥30-point threshold. Longitudinal symptom results.
Later observation windows contain fewer participants. A later percentage can be higher while representing a smaller, more selected set of respondents. It cannot automatically be treated as a prediction for a newly enrolled patient.
Quality of life: a separate self-reported endpoint
This was a general survey item asking whether quality of life had improved relative to baseline. Figure 7C supplies the interval-specific participant counts; these are not the response-curve risk sets.
| Survey interval since first shipment | Participants contributing data | Reporting improved quality of life (95% CI) |
|---|---|---|
| 12–18 months | 2,391 | 81.4% (79.8–82.9%) |
| 18–24 months | 1,378 | 85.7% (83.8–87.5%) |
| 24–30 months | 668 | 89.7% (87.1–91.8%) |
| 30–36 months | 281 | 90.7% (86.8–93.6%) |
| ≥36 months | 52 | 94.2% (84.4–98.0%) |
The smaller later samples and wider confidence intervals matter. These quality-of-life percentages are not a universal success rate for symptom reduction, treatment completion, food tolerance, or all Curex patients.
Medication, adherence, and reported adverse events
- Medication use In Figure 7A, 18.2% reported a 75–100% reduction in medication use at 12–18 months (interval n=2,391), compared with 26.2% at 24–30 months (n=668) and 31.3% at 30–36 months (n=281). These are patient-reported reduction categories, not an instruction to stop medication or evidence that drops caused the reduction.
- Adherence More than 90% reported taking drops on at least 20 days per month across the study intervals. Figure 7D gives interval counts of 2,312 (0–6 months), 1,841 (6–12), 2,391 (12–18), 1,378 (18–24), 668 (24–30), 281 (30–36), and 52 (≥36). This is self-report within a long-term, survey-completing cohort; it is not adherence among all starters or a comparison with shots.
- Discontinuation Forty-two included participants met the paper’s survey-based discontinuation criteria. The definition depended on the number of available follow-up assessments and reported interruptions. Because eligibility already required a year of shipments and qualifying surveys, this cannot be used as a company-wide dropout rate or graduation rate.
- Adverse-event grades Table 4 reports at least one Grade I event in 339/2,897 participants (11.7%), Grade II in 108/2,897 (3.73%), and Grade III in 24/2,897 (0.83%). A person could report more than one grade, so these figures must not be added into a total event rate. No Grade IV or V events, anaphylaxis, or eosinophilic esophagitis were reported in the cohort.
- What the safety figures cannot show Events were patient-reported, and some overlapped with symptoms of underlying allergic disease rather than clearly treatment-attributable reactions. No reported anaphylaxis is not zero risk, proof of safety for every patient, or a safety result for food-allergy drops or at-home injections.
What this study can and cannot support
- A defined care setting.Real-world environmental-allergy drops prescribed through a telemedicine platform, with repeated patient reports over time.
- Multiple outcomes.The paper describes symptom-score trajectories, medication reports, quality of life, adherence, and adverse events rather than one interchangeable success metric.
- A reason to investigate further.The observations can inform prospective research and clinical conversations about expectations, monitoring, and patient selection.
- No untreated or active comparator.There was no randomized comparison with placebo, shots, tablets, another provider, or in-person care. The study cannot establish superiority or the amount of improvement caused by treatment.
- Selection and missing follow-up.The year-of-treatment and survey requirements exclude early discontinuers and people without qualifying responses. Survivor bias, self-report, missing data, regression to the mean, and unmeasured differences can influence results.
- Seasonality and measurement.The authors could not make a unified seasonality adjustment. The ART instrument was not formally externally validated; comparisons to other scales and trials require caution.
- No transfer to another product.These results do not estimate outcomes for children, food-allergy treatment, allergy shots, nasal sprays, eczema creams, or another pharmacy’s or clinic’s protocol.
Funding, author affiliations, and statistical analysis
The funding and conflict-of-interest disclosures state that Curex Inc. funded the study, supplied access to its clinical and survey data, and had personnel involved in study design, data collection, interpretation, and manuscript preparation. Several authors were Curex-affiliated; the author list includes Curex co-founder and medical director Chet Tharpe and co-founder and CEO Gene Kakaulin.
Statistical analysis was independently performed by an Arx Sciartis LLC biostatistician engaged by Curex for biostatistical support. That is a specific disclosure about who performed the analysis. It does not make this an independently funded study or remove the commercial context, author ties, or observational limitations. No external third-party funding was reported.
To cite the study, use the original publication rather than a marketing summary: Tharpe C et al. Front Allergy. 2026;7:1865860. doi:10.3389/falgy.2026.1865860. PMID 42358593; PMCID PMC13290930. A concise, bounded summary is: “In a selected retrospective cohort of 2,897 adults receiving environmental-allergy SLIT through Curex, the estimated probability of a ≥30-point ART symptom-score reduction at least once was 28% by 12 months and 45% by 24 months; there was no comparator.”
Clinical and regulatory context
Curex personalized allergy drops are compounded prescription preparations and are not FDA-approved. FDA approval of an allergenic extract does not approve a compounded drop formulation or its sublingual route. Publication of this cohort does not change that regulatory status. FDA: compounded-drug risks.
A study statistic is not individual clearance for home treatment. People with a history of anaphylaxis or uncontrolled asthma should have an in-person allergy evaluation first; suspected food or drug allergy, young children, and pregnancy also need an appropriate in-person assessment before a home-care decision. The 2024 inhalant-immunotherapy guideline advises against initiating immunotherapy during pregnancy or with uncontrolled asthma. Food challenges require direct medical supervision and must not be attempted at home. Discuss your diagnosis, current treatment, emergency plan, and expected monitoring with your clinician rather than changing medication based on this page.
❓Frequently Asked Questions
It is a company-reported service-scale figure. Curex’s September 29, 2026 company description says more than 50,000 patients treated with at-home allergy immunotherapy; the public About page also reports more than 50,000 patients, checked October 5, 2026. It is not an externally audited count, a market ranking, or the denominator for the 2026 study.
The study reports distinct outcomes rather than one universal success percentage. Its 81.4% figure at 12–18 months describes self-reported quality-of-life improvement among 2,391 interval participants. The separate ≥30-point symptom-response-at-least-once endpoint was estimated at 28% by 12 months and 45% by 24 months. Quality of life, symptom reduction, adherence, and completion are different outcomes.
No. Median survey follow-up was 20 months, and follow-up was uneven. The response-at-least-once analysis used Kaplan–Meier estimates with censoring; its risk set was 2,897 initially, 2,072 at 12 months, and 475 at 24 months. Those risk sets are not survey-window denominators or a basis for converting the 45% estimate into a simple count out of all participants.
Curex funded the study and supplied its platform data. Several authors were Curex-affiliated and contributed to design, data collection, interpretation, and manuscript preparation. Statistical analysis was independently performed by an Arx Sciartis LLC biostatistician engaged by Curex. Independent statistical analysis does not mean an independently funded or wholly unaffiliated study.
No. The analyzed cohort consisted of adults receiving environmental-allergy sublingual drops. It was not a study of food-allergy treatment, children, injections, or every other Curex product. Outcomes from another provider or pharmacy also cannot be transferred to Curex as if they were Curex results.
No. No anaphylaxis was reported in the selected 2,897-person cohort, but rare events, underreporting, and risks in excluded or different populations remain possible. The result is not individual clearance for home treatment. Anaphylaxis history or uncontrolled asthma requires in-person evaluation first; suspected food or drug allergy, children, and pregnancy also need appropriate assessment. Food challenges must not be attempted at home.
General information, not individualized medical advice. Your treating clinician decides eligibility, treatment and dosing. For trouble breathing, throat swelling, faintness or a suspected severe allergic reaction, follow your prescribed emergency plan and call 911.
Sources
Written by Curex editorial team. Medical review has not been recorded.
- Tharpe et al., 2026: PubMed abstract and disclosures (PMID 42358593)
- Full study, tables, figures, funding, and limitations (PMC13290930)
- About Curex: company-reported scale, checked October 5, 2026
- FDA: Understanding the Risks of Compounded Drugs
- 2024 Clinical Practice Guideline: Immunotherapy for Inhalant Allergy